SG2285, a novel C2-aryl-substituted pyrrolobenzodiazepine dimer prodrug that cross-links DNA and exerts highly potent antitumor activity

Cancer Research

Volumn 70, Issue 17, 2010, Pages 6849-6858

  Hartley, John A ^a   Hamaguchi, Anzu ^a   Coffils, Marissa ^a   Martin, Christopher R H ^a   Suggitt, Marie ^a   Chen, Zhizhi ^b   Gregson, Stephen J ^b   Masterson, Luke A ^b   Tiberghien, Arnaud C ^b   Hartley, Janet M ^a   Pepper, Christopher ^c   Lin, Thet Thet ^c   Fegan, Christopher ^c   Thurston, David E ^b   Howard, Philip W ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CISPLATIN; DOCETAXEL; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; IRINOTECAN; PACLITAXEL; SG 2202; SG 2285; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; BENZODIAZEPINE DERIVATIVE; PRODRUG; PYRROLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CANCER CELL CULTURE; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; CROSS LINKING; DNA REPAIR; DNA STRAND; DRUG MECHANISM; DRUG POTENCY; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; T LYMPHOCYTE; ANIMAL; CHO CELL LINE; CRICETULUS; DRUG SCREENING; FEMALE; HAMSTER; NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BENZODIAZEPINONES; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; HUMANS; MICE; NEOPLASMS; PRODRUGS; PYRROLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77956271552     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0790     Document Type: Article

References (31)

1. Thurston DE. Advances in the study of pyrrolo[2,1-c][1,4]benzodiazepine (PBD) antitumor antibiotics. In: Neidle S, Waring MJ, editors. Molecular aspects of anticancer drug-DNA interactions. London: The Macmillan Press Ltd; 1993, p. 54-88.
2. Hurley LH, Reck T, Thurston DE, et al. Pyrrolo(1,4)benzodiazepine antitumor antibiotics: relationship of DNA alkylation and sequence specificity to the biological activity of natural and synthetic compounds. Chem Res Toxicol 1988;1:258-68.
3. Bose DS, Thompson AS, Ching J, et al. Rational design of a highly efficient irreversible DNA interstrand cross-linking agent based on the pyrrolobenzodiazepine ring system. J Am Chem Soc 1992;114:4939-41.
4. Bose DS, Thompson AS, Smellie M, et al. Effect of linker length on DNA-binding affinity, cross-linking efficiency and cytotoxicity of C8-linked pyrrolobenzodiazepine dimers. J Chem Soc Chem Commun 1992;14:1518-20.
5. Thurston DE, Bose DS, Thompson AS, et al. Synthesis of sequence-selective C8-linked pyrrolo[2,1-c][1,4]benzodiazepine DNA interstrand crosslinking agents. J Org Chem 1996;61:8141-7.
6. Gregson SJ, Howard PW, Hartley JA, et al. Design synthesis and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity. J Med Chem 2001;44:737-8.
7. Gregson SJ, Howard PW, Gullick DR, et al. Linker length modulates DNA crosslinking reactivity and potency for ether-linked C2-exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers. J Med Chem 2004;47:1161-74.
8. Smellie M, Kelland LR, Thurston DE, Souhami RL, Hartley JA. Cellular pharmacology of novel C8-linked anthramycin-based sequence-selective DNA minor-groove cross-linking agents. Br J Cancer 1994;70:48-53. (Pubitemid 2105805)
9. Smellie M, Bose DS, Thompson AS, Jenkins TC, Hartley JA, Thurston DE. Sequence selective recognition of duplex DNA through covalent interstrand crosslinking: kinetic and molecular modelling studies with pyrrolobenzodiazepine (PBD) dimers. Biochemistry 2003;42:8232-9.
10. Martin C, Ellis T, McGurk CJ, et al. Sequence-selective interaction of the minor-groove interstrand cross-linking agent SJG-136 with naked and cellular DNA: footprinting and enzyme inhibition studies. Biochem 2005;44:4135-47.
11. Hartley JA, Spanswick VJ, Brooks N, et al. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity. Part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity. Cancer Res 2004;64:6693-9.
12. Alley MC, Hollingshead MG, Pacula-Cox CM, et al. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity. Part 2: efficacy evaluations. Cancer Res 2004;64:6700-6.
13. Hochhauser D, Meyer T, Spanswick VJ, et al. Phase 1 study of a sequence selective minor groove DNA binding agent (SJG-136) with pharmacokinetic and pharmacodynamic measurements in patients with advanced solid tumors. Clin Cancer Res 2009;15:2140-7.
14. Puzanov I, Lee W, Berlin JD, et al. Final results of phase I and pharmacokinetic trial of SJG-136 administered on a daily x3 schedule. Proc Am Soc Clin Oncol Ann Meet J Clin Oncol 2008;26:Abs 2512.
15. Janjigian YY, Lee W, Kris MG, et al. A phase I trial of SJG-136 (NSC694501) in advanced solid tumors. Cancer Chemother Pharmacol 2010;65:833-8.
16. Cooper N, Hagan DR, Tiberghien A, et al. Synthesis of novel C2-aryl pyrrolobenzodiazepines (PBDs) as potential antitumour agents. Chem Commun 2002;16:1764-5. (Pubitemid 34924945)
17. Howard PH, Chen Z, Gregson SJ, et al. Synthesis of a novel C2/C2′-aryl-substituted pyrrolo[2,1-c]-[1,4]benzodiazepine dimer prodrug with improved water solubility and reduced DNA reaction rate. Bioorganic Med Chem Lett 2009;19:6463-6.
18. Clingen PH, De Silva IU, McHugh PJ, et al. The XPF-ERCC1 endonuclease and homologous recombination contribute to the repair of minor groove DNA interstrand crosslinks in mammalian cells produced by the pyrrolo[2,1-c][1,4] benzodiazepine dimer SJG-136. Nucleic Acids Res 2005;33:3283-91.
19. Hartley JM, Spanswick VJ, Gander M, et al. Measurement of DNA crosslinking in patients on ifosfamide therapy using the single cell gel electrophoresis (comet) assay. Clin Cancer Res 1999;5:507-12.
20. Spanswick VJ, Hartley JM, Ward TH, Hartley JA. Measurement of drug-induced DNA interstrand crosslinking using the single cell gel electrophoresis (comet) assay. In: Brown R, Boger-Brown U, editors. Methods in molecular medicine. Vol. 28: cytotoxic drug resistance mechanisms. New York: Humana Press; 1999, p. 143-54.
21. Pepper C, Thomas A, Hidalgo de Quintana J, Davies S, Hoy T, Bentley P. Pleiotropic drug resistance in B-cell chronic lymphocytic leukaemia - the role of Bcl-2 family proteins. Leuk Res 1999;23:1007-14. (Pubitemid 29488647)
22. Cartwright R, Tambini CE, Simpson PJ, Thacker J. The XRCC2 DNA repair gene from human and mouse encodes a novel member of the recA/RAD51 family. Nucleic Acids Res 1998;26:3084-9.
23. Liu N, Lamerdin JE, Tebbs RS, et al. XRCC2 and XRCC3, new human Rad51-family members, promote chromosome stability and protect against DNA cross-links and other damages. Mol Cell 1998;1:783-93. (Pubitemid 128379063)
24. Yamada NA, Hinz JM, Kopf VL, Segalle KD, Thompson LH. XRCC3 ATPase activity is required for normal XRCC3-51C complex dynamics and homologous recombination. J Biol Chem 2004;279:23250-4.
25. Yokoyama H, Sarai N, Kagawa W, et al. Preferential binding to branched DNA strands and strand-annealing activity of the human Rad51B, Rad51C, Rad51D and Xrcc2 protein complex. Nucleic Acids Res 2004;32:2556-65.
26. Kuraoka I, Kobertz WB, Ariza RR, Biggerstaff M, Essigmann JM, Wood RD. Repair of an interstrand DNA cross-link initiated by ERCC1-XPF repair/recombination nuclease. J Biol Chem 2000;275:26632-6.
27. De Silva IU, McHugh PJ, Clingen PH, Hartley JA. Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol Cell Biol 2000;20:7980-90.
28. De Silva IU, McHugh PJ, Clingen PH, Hartley JA. Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin. Nucleic Acids Res 2002;30:3848-56.
29. McHugh PJ, Spanswick VJ, Hartley JA. Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol 2001;2:483-90.
30. Pepper CJ, Hambly RM, Fegan CD, Delavault P, Thurston DE. The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill. Cancer Res 2004;64:6750-5.
31. Lee JS, Dixon DO, Kantarjian HM, Keating MJ, Talpaz M. Prognosis of chronic lymphocytic leukemia: a multivariate regression analysis of 325 untreated patients. Blood 1987;69:929-36.